Abstract: Tumour thrombosis is a relatively rare complication of solid cancers, with occult inferior vena cava(IVC) tumour thrombosis having a reported incidence rate of 0.11%. Renal cell carcinoma(RCC) has a propensity to extend as tumour thrombus into the renal vein and IVC. The preoperative assessment for the presence and extent of renal vein and IVC tumour thrombus is important for planning appropriate surgical resection. There are reports having described the diagnosis of tumour thrombosis by Fluorine-18 fluorodeoxyglucose positron emission tomography and Computed tomography (F-18 FDG PET/CT). We present two cases, one with right RCC showing renal vein and IVC tumour invasion and another left RCC with renal vein, IVC and hepatic vein thrombosis detected using FDG PET/CT.
INTRODUCTION
Tumour thrombus is one of the rare complications of renal cell carcinoma (RCC), Wilm's tumour, testicular tumour, adrenal cortical carcinoma, lymphoma, pancreatic cancer, osteosarcoma, Ewing's sarcoma and hepatocellular carcinoma [1] . RCC is an aggressive neoplasm with potential dissemination to the renal veins and IVC in 24% and 12% of all cases, respectively [2] . In a few instances, RCC venous extension may go beyond the IVC, reaching the hepatic vein and even right atrium. RCC venous involvement carries a serious outcome prognosis and necessitates an in-depth imaging evaluation and staging before surgery and thrombectomy [3] . The diagnosis is usually made accidentally during staging investigations. Recent introduction of FDG PET/CT technology has revolutionized by fusing functional and anatomical criteria for staging of most cancers, thus allowing accurate anatomical localization of tumour spread and providing the ability to differentiate between tumour and blood thrombus [4] . 
DISCUSSION
Venous thromboembolism (VTE) is a wellrecognized and relatively frequent complication of malignancy. Tumour thrombosis, in contrast, is a rare complication of solid cancers such as colon, pancreas, hepatocellular carcinoma and RCC, and has also been described in lymphoma and sarcoma [4] . The correct diagnosis of tumour thrombosis and its differentiation from VTE can alter patient management and prevent unnecessary long-term anticoagulation treatment. RCC is an aggressive neoplasm with potential dissemination to the renal veins and IVC in 24% and 12% of all cases, respectively [5] . Accurate tumour staging in patients with RCC is essential before surgical management. Extension of tumour thrombus into the renal vein or IVC is a known complication of RCC with significant prognostic and therapeutic implications. Thrombus extension above the diaphragm and into the right atrium may require thoracotomy and resection of affected vena cava segments in addition to Axial images (C) of fused PET/CT shows FDG uptake with maximum standardized uptake value (SUVmax) of 24 in the liver which corresponds to the right hepatic vein suggestive of thrombosis.
nephrectomy [6] . Patients with RCC may also be hypercoagulable and develop bland caval thrombus that may not require caval resection or thrombectomy. Distinguishing between these 2 entities is not usually possible with enhanced computerized tomography (CT) or magnetic resonance imaging [7] .
FDG PET/CT imaging is limited in the identification of primary urologic neoplasms resulting from the proximity of physiological radiotracer uptake in the normal genitourinary system. However, FDG PET/CT is capable of detecting regional and distant urologic metastases presenting with a better target-tobackground signal ratio away from physiological foci of
F-18 FDG accumulation [8] . Only sporadic reports have described the diagnosis of tumour thrombosis by positron emission tomography with 18F-fluorodeoxyglucose [9, 10] . Positive FDG PET/CT demonstration of venous tumour thrombus has been previously reported in IVC related to RCC [11] Although only limited data exist in the literature, it appears that 18F-FDG-PET scans can be used to accurately differentiate between septic and aseptic deep vein thrombosis [12] . Septic lesions have increased uptake of 18-FDG, whereas aseptic deep vein thromboses have been reported to exhibit normal biodistribution of the agent. These findings were the basis for the assumption that FDG imaging by PET/CT may differentiate between tumour thrombosis and VTE as well. Davidson et al. [13] described Accuracy of FDG PET/CT to differentiate between tumour thrombosis and benign VTE was 100% in a small study. Sharma et al. [14] recently described 24 patients with tumour thrombus of different etiology and concluded that the mean maximum standardized uptake value (SUVmax) was 3.2 (range: 2.3-4.6; median: 3.3) in the benign thrombosis group and was 6.0 (range: 2.3-13.8; median: 3.3) in the tumour thrombosis group and FDG PET-CT can detect active tumour thrombosis and is helpful in differentiating it from benign thrombus. Our patients had SUVmax of 21 and 34 which help in accurately differentiate tumour thrombus.
CONCLUSION
FDG PET/CT accurately differentiated tumour thrombosis from benign venous thrombi in our patients. FDG PET/ CT appears to be beneficial in the diagnosis of occult tumour thrombosis and may be used as a non-invasive tool to characterize suspicious thrombotic lesions, both above and below the diaphragm. By furthering the diagnosis and recognition of tumour thrombi by PET/CT may consequently improve patient management. These case serves as a reminder that special attention should always be paid to the IVC and adjoining venous drainage pathways for abnormal FDG activity, particularly when imaging RCC, as the diagnosis of venous tumour thrombus has important clinical ramifications.
